Cystinuria is a rare genetic disorder caused by mutations in the genes that encode the two subunits of amino acid transport, resulting in failure of absorption of filtered dibasic amino acids including cystine in the proximal tubules. Despite new knowledge of the molecular basis of cystinuria, it continues to be one of the most challenging stone diseases. There is no curative treatment of cystinuria, and patients will have life-long risk of stone formation, repeated surgery, impaired renal function and quality of life. Management of cystinuria requires a multi-modal approach in dedicated centres to improve treatment outcome and patient compliance. Recent developments in cystine crystal growth inhibitors may hold promise for more effective stone prevention in the future.
Introduction
Cystinuria is a rare genetic condition that continues to be one of the most challenging kidney stone diseases. It is caused by mutations in the genes that encode the two subunits of the amino acid transport, resulting in failure of absorption of filtered dibasic amino acids including cystine in the proximal tubules 1 . Since cystine has a very limited solubility in the physiological range of urine pH, this leads to complicated and recurrent kidney stone formation, harbouring a higher risk of chronic kidney disease than the more common calcium oxalate kidney stone disease. Cystinuria represents approximately 1% of adult and 3-10% of pediatric stone disease 1, 2 . The worldwide prevalence of cystinuria is approximately 1 in 7000 neonates, ranging from approximately 1:2000 at the Mediterranean East Coast to 1:100000 in Sweden 2, 3 .
Genetic basis of cystinuria
The inheritance pattern of cystinuria is complex. Traditionally, cystinuria has been classified into three different subtypes. Later this classification was criticised, and a new classification based on the affected genes SLC3A1 and SLC7A9 was made by Della Strologo et al. 4 .
Cystinuria type A is caused by mutations in the SLC3A1 gene located on chromosome 2. The SLC3A1 gene encodes the heavy subunit of the renal amino acid transporter (rBAT), which is needed to localize the transporter to the plasma membrane 5 . The mode of inheritance appears to be truly autosomal recessive and the penetrance is high 6 . An affected person has two faulty copies of the gene and each of the parents carries one copy. Carriers usually have normal level of urine cystine and they have no increased risk of developing urolithiasis compared with the general population 5 . . Carriers such as parents, siblings and children often have raised urine cystine levels and stone formation is reported in 2-18% of cases 4, 6 . In more rare cases the patient has mutations in both genes (SLC3A1+SLC7A9). This subgroup is classified as cystinuria type AB. The frequency is reported to be 1.2% -4% 4, 8, 9 . 
Diagnosis
Diagnosis is based on medical history, stone analysis, laboratory investigations and imaging. Cystinuria should always be suspected in case of early kidney stone debut (< 20 years) and a family history of cystinuria.
Stone analysis and laboratory investigations
A stone analysis should be performed whenever possible. Pure cystine stones are observed in the majority of cases 12 . Microscopy of urine revealing hexagonal crystals are pathognomonic 2, 13 . Cyanide-nitroprusside colorimetric test detects cystine in urine at a threshold concentration of 75 mg/l. A quantitative chromatographic analysis of a 24-hour urine-sample confirms the diagnosis. The normal rate of cystine excretion is around 0.10 mmol/day; homozygote cystinurics usually excrete more than 1.7 mmol/day.
Imaging
Cystine stones are weak radiopaque on plain radiographs. The attenuation value (Hounsfield Unit, HU) of cystine stones on Computerized Tomography (CT) varies
.
A low HU may support the suspicion of cystine stones, but there is significant overlapping between stones of different compositions, especially for cystine and uric acid stones, making a definitive differentiation challenging [15] [16] [17] . Dualenergy CT and automated image processing may improve the differentiation 18, 19 . CT may also be helpful in predicting fragility of the stone by evaluating morphology of the stone, inhomogeneous stones with void regions being more fragile [20] [21] [22] ( Figure 1 ). Renal ultrasonography is less accurate but represents the mainstay for follow-up of cystine stone formers to avoid frequent exposure to radiation.
Surgical management
Despite aggressive medical therapy, cystinuric patients are likely to suffer frequent recurrent episodes of stones necessitating urologic intervention 13 . Cystinuric patients will often have experienced previous invasive procedures, demanding use of the least invasive methods to minimize complications and morbidities of multiple procedures 11 . On the other hand, since residual fragments after stone treatment in cystinuric patients sooner or later will result in symptomatic stone disease, complete stone clearance is of upmost importance. Thus, the surgical challenge in cystinuria is to find the balance between the safety of the procedures and the need for complete stone clearance 23 .
Cystine calculi are generally considered Shock Wave Lithotripsy (SWL) resistant. Pre-treatment imaging may reliably predict outcome of SWL, however; heterogeneous stones being more fragile to shock waves (SW) than homogeneous stones 21 . Thus, patients suitable for SWL may be selected by the appearance of the stone on NonContrast CT (NCCT). Smaller (<2 cm) SW resistant cystine calculi may effectively be managed ureteroscopically using flexible ureteroscopes and laser lithotripsy 11, 23, 24 , whereas larger and branched (staghorn) stones most effectively are managed by percutaneous nephrolithotomy (PCNL). Newer approaches of PCNL with minituarization of the tract (Mini PCNL) may be especially suitable for cystinuric patients reducing morbidity related to repeated renal accesses. No systemic therapies can effectively dissolute cystine stones. A significant increase in cystine solubility begins, when pH exceeds 7.0 25 . Chemolytic dissolution of cystine stones through a nephrostomy tube or ureteral catheter may be done with the highly alkaline solution THAM (tris-hydroxymethyl-amminomethane) or the chelating solution acetylcysteine 2%, or preferably the two solutions in combination 26, 27 . Instillation therapy for cystine stones are normally performed secondary to SWL, PCNL or ureterorenoscopy for dissolution of residual stone fragments, since chemolysis monotherapy of most cystine stones will require long periods of irrigation 25, 27 . Due to advances in minimal invasive procedures chemolytic procedures are only rarely needed 11 .
Stone prevention
The mainstay of treatment consists of urinary dilution, urinary alkalinization and reduction of cystine to its more soluble metabolite, cysteine, using thiol-binding agents 28, 29 .
There are no controlled prospective trials using stone formation as an endpoint for any therapy for cystinuria. However, studies using endpoints of cystine excretion and studies of stone passage using patients as their own historical controls provide reasonable data on which to base therapeutic choices.
Dietary measures
Urinary dilution: Increasing urine flow rate will reduce cystine concentration, thereby decreasing level of cystine saturation in urine. The level of urine flow required is dependent on the patient's cystine excretion, but most adult patients need to produce at least 3.5 liters of urine per day to prevent stone formation. It is usually recommended that the patient awaken at least once per night to void and drink additional water 28, 29 . Sodium: It has been shown in several studies that sodium loading increases urinary cystine excretion, and that sodium restriction is anticystinuric [30] [31] [32] . Cystinuric patients should be advised to reduce sodium intake (< 2 g/ day) 27 . Dietary intake of sodium may be assessed by urine sodium excretion.
Protein: Potentially, protein restriction should be attractive in cystinuric patients in order to reduce intake of the sulphur-containing amino acid methionine, from which sulphur is derived for cystine formation. Only one study has explored the quantitative effect of protein restriction on cystine excretion 33 . In this study a low-protein diet reduced cystine excretion by 20% compared to a high-protein diet. A reduction of that magnitude seems to be very modest in light of the potential malnutrition problems a low-protein diet might induce in this population. On the other hand, it seems advisable to maintain a normal protein intake, and avoid protein gluttony, since this additionally will reduce the dietary acid load, thereby increasing urine pH and cystine solubility 34, 35 . The dietary content of protein should not exceed 0.8 g/kg body mass/day.
Pharmacologic treatment
Urinary alkalinisation: Cystine solubility increases with increasing pH, however, solubility does not increase significantly until a level of urine pH above 7-7.5 is reached. To achieve this goal requires significant and frequent doses of alkali, what the majority of patients find difficult to comply 30 . Furthermore, the optimal dose of alkali is difficult to estimate in any given patient, since it has been shown that cystine solubility varies considerably between individuals 36 . Urine dilution in itself results in an increase in pH, and the combination of urine dilution and alkali therapy is the fundamental first step in cystinuria management. Furthermore, increasing urine pH increases the cystinesolubilizing efficacy of thiol drugs (see below) 37 . Potassium alkali seems to be preferable, since sodium alkali will increase cystine and calcium excretion, the latter potentially increasing the risk of calcium phosphate crystallization in an alkaline urine 28, 29, 35 . Patient-monitored control of urine pH is important for successful alkalinisation therapy.
Thiol-binding agents:
Sulfhydroxyl compounds, such as D-penicillamine or tiopronin (α-mercaptopropionylglycine), can reduce the formation of cystine crystals by reacting with cystine and generating more soluble mixed disulfide compounds (drug-cysteine complex). No RCTs are available, but both drugs seem to have the capability of reducing stone recurrences [38] [39] [40] [41] . Both D-penicillamine and tiopronin have significant side effects within the usual range of therapeutic dosage (1000-2000 mg/day), including foul odor, nausea, fever, fatigue, skin rash, premature skin aging, proteinuria and hypersensitivity 42 , which restricts their use to patients who are unable to control stone formation with high fluid intake, dietary modification and urine alkalinisation (Figure 2 ). Side effects of thiols seem to be less prominent with the use of tiopronin compared to D-penicillamine 39 .
If the patients are intolerant to D-penicillamine and α-mercaptopropionylglycine, the thiol captopril may be tried, although the role of captopril in the treatment of cystinuria is debatable 43, 44 . In vitro findings have shown that increasing urine pH greatly increases the effect of thiol drugs to solubilize cystine in a clinically relevant time frame, highlighting the importance of combining thiol with alkali therapy 37 . Investigation of newer thiol-containing drugs (cysteamine and 2,3 dimercaptosuccinic acid (DMSA)) has not yet lead to clinical use 45, 46 .
Cystinuria treatment pipeline
Despite above mentioned treatment options, a significant proportion of patients experience severe relapsing renal stone disease, and new more effective preventive treatment options are highly warranted. Recently, the application of atomic force microscopy to cystinuria has identified L-Cystine dimethylester (CDME) as an effective molecular imposter of L-Cystine, capable of inhibiting crystal growth in vitro 47 . The potential of CDME was further highlighted by demonstration of its ability to inhibit cystine crystal growth in vivo utilizing a murine model 48 . Subsequent development of L-Cystine diamides more effective than CDME with respect to sustaining higher concentrations of L-Cystine in solution 49 , which is tantamount to inhibition of crystal growth, might represent a long-awaited breakthrough in cystinuria management. Future clinical trials hopefully will confirm these promising results.
Follow-up and patient compliance
Close follow-up of patients are important to identify stone recurrences and monitor side-effects of pharmacologic therapy. Cystine stones in the early course of a recurrence tend to be heterogeneous, highlighting the importance of regular follow-up (every 3-6 months), in order to offer the patients the least invasive treatment options.
Failure of pharmacological therapy may to a large extend be contributed compliance problems. It has been shown that the need for urological intervention for recurrent stones decreased with medical compliance, and that introduction of a dedicated cystinuria clinic halved intervention rate 50 . Centralizing the management of patients with cystinuria to dedicated centers, therefore, may be an equally important step towards better management of this complicated group of stone patients. An algoritm for the medical management of cystinuria is presented in Figure 2 .
Conclusion
Evaluating and treating cystinuria continues to represent a major challenge. Pharmacotherapy of this serious stone disease has not improved in decades despite new knowledge on the molecular-genetic basis of the disease, however, recent studies implying cystine growth inhibition through molecular mimicry, may introduce a completely new paradigm for effective stone prevention in cystinuria. Cystinuric patients should be managed in dedicated centres offering minimal invasive treatment modalities, enabling personalized treatment and increasing patient compliance.
